ArticleBMC public health2025
Temporal trends of low back pain burden and joinpoint and age-period-cohort analysis in China from 1990 to 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe burden of low back pain (LBP) is increasing rapidly. This study aimed to analyze the temporal trends of the LBP burden in China from 1990 to 2021.
methodsData from the Global Burden of Disease (GBD) 2021 were used to examine the crude and age-standardized rates, along with their uncertainty interval (UI), for incidence, prevalence and disability adjusted life years (DALYs) per 100,000 for LBP, stratified by sex. The joinpoint regression model was applied to calculate the annual percent change (APC) and corresponding 95% confidence interval (CI) for the LBP burden. Additionally, an age-period-cohort analysis was conducted to assess the temporal trends in the LBP burden.
resultsIn 2021, LBP affected 100,093,745 individuals in China. The crude incidence, prevalence and DALYs rates were 3.05% (95% UI: 2.64-3.46%), 7.04% (95% UI: 6.12-7.94%) and 794.08 per 100,000 (95% UI: 557.48-1077.36), respectively. From 1990 to 2021, the age-standardized incidence, prevalence and DALYs rates declined annually by 0.71% (95% CI: 0.67-0.75%), 0.79% (95% CI: 0.75-0.83%), and 0.79% (95% CI: 0.75-0.84%), respectively. The LBP burden was higher in females than in males, with incidence rates rising with age. From the age of 45 onward, women exhibited significantly higher incidence rates than men. Over the past three decades, both period-specific and cohort-specific LBP incidence showed a downward trend.
conclusionLBP remains a substantial public health burden in China, with variations across sex, age, period and cohort. Targeted healthcare policies and resource allocation should be prioritized for high-risk populations, particularly older adults and females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.